TD Cowen Downgrades Aerovate Therapeutics Inc (AVTE) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/12/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Dell shares surge on record AI server bookings
- 'No panic anywhere' may be the problem, BofA strategists warn
- Kroger cuts same-store sales outlook, keeps earnings guidance
- AstraZeneca's camizestrant fails primary endpoint in breast cancer trial
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Evercore ISI Downgrades Aerovate Therapeutics Inc (AVTE) to In Line
June 17, 2024 4:01 PM EDTEvercore ISI analyst Liisa Bayko downgraded Aerovate Therapeutics Inc (NASDAQ: AVTE) from Outperform to In Line with a price target of $2.00 (from $27.00).
The analyst ocmments "AV-101, inhaled form of imatinib, was an abject failure in PAH, showing no clinically relevant benefit on PVR... More
Jefferies Downgrades Aerovate Therapeutics Inc (AVTE) to Hold
June 17, 2024 12:15 PM EDTJefferies analyst Eun Yang downgraded Aerovate Therapeutics Inc (NASDAQ: AVTE) from Buy to Hold with a price target of $2.00 (from $65.00).
The analyst comments "AVTE announced that the Phase IIB failed in PAH and that none of the 3 doses demonstrated a clinically meaningful improvement in PVR.... More
Guggenheim Downgrades Aerovate Therapeutics Inc (AVTE) to Neutral
June 17, 2024 12:15 PM EDTGuggenheim analyst Vamil Divan downgraded Aerovate Therapeutics Inc (NASDAQ: AVTE) from Buy to Neutral.
For an analyst ratings summary and ratings history on Aerovate Therapeutics Inc click here. For more ratings news on Aerovate Therapeutics Inc click here.
Shares of Aerovate Therapeutics Inc closed at $24.62 yesterday.
... MoreBTIG Downgrades Aerovate Therapeutics Inc (AVTE) to Neutral
June 17, 2024 10:39 AM EDTBTIG analyst Julian Harrison downgraded Aerovate Therapeutics Inc (NASDAQ: AVTE) from Buy to Neutral.
The analyst comments "AV-101 did not separate from placebo on its primary endpoint in the Phase 2b portion of IMPAHCT. All doses of AV-101 failed to meet stat sig on PVR at... More
Wedbush Downgrades Aerovate Therapeutics Inc (AVTE) to Neutral
June 17, 2024 9:37 AM EDTWedbush analyst Andreas Argyrides downgraded Aerovate Therapeutics Inc (NASDAQ: AVTE) from Outperform to Neutral with a price target of $3.00 (from $41.00).
For an analyst ratings summary and ratings history on Aerovate Therapeutics Inc... More
Aerovate Therapeutics (AVTE) to Resume Trading at 9 a.m.
June 17, 2024 8:42 AM EDTAerovate Therapeutics (NASDAQ: AVTE) to Resume Trading at 9 a.m.
AV-101 did not meet the primary endpoint of change in pulmonary vascular resistance (PVR) for any of the studied doses... MoreAerovate Therapeutics (AVTE) Reports 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Trial
June 17, 2024 8:32 AM EDTAerovate Therapeutics, Inc. (Nasdaq: AVTE) today announced topline results from the Phase 2b portion of the Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT), a Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multi-national trial of AV-101, a novel dry powder inhaled formulation of imatinib, in adults with pulmonary arterial hypertension (PAH).
The objective of the Phase 2b portion of IMPAHCT was to assess the efficacy, safety and tolerability of three different doses of... More
